Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.56 |
| ▸ | MEN1 | O00255 | 8/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 9/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MYOC | Q99972 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392922 | 0.87 | KMT2A (0.54) | KMT2AMEN1GAALMNAMAPT | |
| SCHEMBL1651305 | 0.85 | KMT2A (0.53) | KMT2AMEN1GAALMNAMAPT | |
| Hydrochloric Acid SCHEMBL11567226 | 0.85 | KMT2A (0.53) | KMT2AMEN1GAALMNAMAPT | |
| SCHEMBL6918119 | 0.82 | MAPT (0.70) | KMT2AMEN1GAALMNAMAPT | |
| SCHEMBL31675108 | 0.82 | KMT2A (0.50) | KMT2AMEN1GAALMNAMAPT | |
| SCHEMBL11567116 | 0.81 | KMT2A (0.48) | KMT2AMEN1GAALMNAMAPT | |
| SCHEMBL29111764 | 0.81 | KMT2A (0.62) | KMT2AMEN1GAALMNAMAPT | |
| SCHEMBL29111760 | 0.81 | KMT2A (0.62) | KMT2AMEN1GAALMNAMAPT | |
| SCHEMBL29111851 | 0.81 | KMT2A (0.62) | KMT2AMEN1GAALMNAMAPT | |
| SCHEMBL642700 | 0.80 | KMT2A (0.81) | KMT2AMEN1GAALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737566-A1 | CAS12 PROTEIN AND USE THEREOF | Reforgene Medicine (CN) | 2026-05-06 | — | — | EP | claimed |
| EP-4692338-A1 | CAS12 PROTEIN AND USE THEREOF | Guangzhou Reforgene Medicine Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| WO-2025061113-A1 | CAS12 PROTEIN AND USE THEREOF | 广州瑞风生物科技有限公司 | 2025-03-27 | — | — | WO | claimed |
| WO-2025059391-A2 | ANTI-CDH17 ANTIBODY-DRUG CONJUGATE AND METHOD OF MAKING AND USING THEREOF | TENMED LIFE SCIENCE LTD (CN) | 2025-03-20 | — | — | WO | claimed |
| CN-116459802-B | High-strength three-dimensional continuous oversized hole uranium adsorption hydrogel and preparation method thereof | 北京理工大学 | 2024-09-24 | — | — | CN | claimed |
| CN-117924106-A | Ionizable lipid compounds | 北京剂泰医药科技有限公司 | 2024-04-26 | — | — | CN | claimed |
| WO-2024078645-A2 | CAS PROTEIN AND USE THEREOF | 广州瑞风生物科技有限公司 | 2024-04-18 | — | — | WO | claimed |
| CN-117243922-A | lipid nanoparticles | 北京剂泰医药科技有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-116969851-A | Ionizable lipid compounds | 北京剂泰医药科技有限公司 | 2023-10-31 | — | — | CN | claimed |
| EP-3813295-B1 | METHOD AND SYSTEM FOR DLT NETWORKS CONSENSUS ENHANCEMENT USING QUANTUM COMPUTING MECHANISMS | TELEFONICA IOT & BIG DATA TECH S A (ES) | 2023-10-18 | — | — | EP | claimed |
| US-20230303744-A1 | SYNTHESIS OF A CATIONIC SURFMER AND ITS COPOLYMERS FOR ENHANCED OIL RECOVERY | SAUDI ARABIAN OIL COMPANY (SA) | 2023-09-28 | — | — | US | claimed |
| CN-116670283-A | RNA therapeutics and methods of use thereof | 伊莱利利公司 | 2023-08-29 | — | — | CN | claimed |
| CN-105813660-B | Wound care article with superabsorbent fibers and superabsorbent particles | BSN医疗有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-11637711-B2 | Method and system for DLT networks consensus enhancement using quantum computing mechanisms | TELEFÓNICA IOT & BIG DATA TECH, S.A. (ES) | 2023-04-25 | — | — | US | claimed |
| CN-114145757-B | Electroencephalogram signal reconstruction method based on asymmetric synthesis filter bank | 广东工业大学 | 2022-05-10 | — | — | CN | claimed |
| CN-114145757-A | Electroencephalogram signal reconstruction method based on asymmetric synthesis filter bank | 广东工业大学 | 2022-03-08 | — | — | CN | claimed |
| US-20220025090-A1 | SYNTHESIS OF A CATIONIC SURFMER AND ITS COPOLYMERS FOR ENHANCED OIL RECOVERY | SAUDI ARABIAN OIL COMPANY (SA) | 2022-01-27 | — | — | US | claimed |
| WO-2022019927-A1 | SYNTHESIS OF A CATIONIC SURFMER AND ITS COPOLYMERS FOR ENHANCED OIL RECOVERY | SAUDI ARABIAN OIL COMPANY (SA) | 2022-01-27 | — | — | WO | claimed |
| US-20260146265-A1 | CAS12 PROTEINS AND USES THEREOF | REFORGENE MEDICINE (CN) | 2026-05-28 | — | — | US | disclosed |
| EP-0246978-A1 | Reagent for rendering biological fluids transparent and its analytical applications | UNIVERSITE DE NANCY I (FR) | 1987-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146265-A1 | CAS12 PROTEINS AND USES THEREOF | PHAX, STING1, TTLL12 | KMT2A 2550/4885MEN1 2398/4885GAA 2594/4885 |
| US-20230303744-A1 | SYNTHESIS OF A CATIONIC SURFMER AND ITS COPOLYMERS FOR ENHANCED OIL RECOVERY | SURF4, SRP54, FFAR3 | KMT2A 4355/4885MEN1 4243/4885GAA 4866/4885 |
| US-20220025090-A1 | SYNTHESIS OF A CATIONIC SURFMER AND ITS COPOLYMERS FOR ENHANCED OIL RECOVERY | SURF4, SRP54, FFAR3 | KMT2A 4352/4885MEN1 3889/4885GAA 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.